Introduction
Neo-angiogenesis is a primordial step for tumor growth and metastasis and its targeting is under investigation in many solid tumors (1) (2) (3) (4) . Human cancer cells express elevated levels of proangiogenic factors (5) . Among them the role of vascular endothelial growth factor (VEGF-A) in tumor progression has been clearly established (6) . Elevated expression of circulating VEGF-A is associated with poor prognosis in metastatic colorectal, lung, and renal cancer (7) . Subsequently the first anti-angiogenic molecule developed to impair neo-angiogenesis targeted VEGF. Bevacizumab (Avastin, Genentech Inc., San Francisco, CA) is a humanized monoclonal antibody directed against all isoforms of VEGF-A (8) . Bevacizumab prevents the binding of VEGF-A to its receptor VEGF-R1 (Flt-1) and R2 (Flt-2, or KDR). Although the function of VEGF-R2 in tumor angiogenesis has been characterized thoroughly, the function of VEGF-R1 is not yet well defined (9) . Bevacizumab has been found clinically active in many solid tumors, such as colon, nonsmall cell lung, metastatic renal cell carcinoma or glioblastoma (10) (11) (12) (13) .
Currently the Food and Drug Administration approves its use in combination with chemotherapy/immunotherapy in colon, lung and renal cancers and in glioblastoma as a single agent. The mechanisms of action of bevacizumab are not perfectly understood. It could act by sequestering VEGF-A in the blood and/or tumor interstitium or induce normalization of VEGF-A concentration in these compartments (14) . Despite initial efficacy, the withdrawal of bevacizumab can be associated to rapid tumor re-growth or a ''rebound'' phenomenon with accelerated clinical decline in patients (15, 16) .
Moreover, in case of tumor progression under bevacizumab, salvage chemotherapy has been quite inefficient, suggesting the emergence of a treatment-resistant phenotype (17). Most tumors will develop resistance to bevacizumab on a long term (18) . While vessels were perceived as passively conducting nutrients to tumor cells, recent reports underline the perfusionindependent role of the endothelium. In such context endothelial cells (ECs) participate to an active cross-talk with tumor cells, resulting in the modification of their phenotype (19) . ECs isolated from various tumors acquired genotype alterations as aneuploidie, or abnormal multiple chromosomes (20) or displayed an activated profile through Pi3/Akt or MAPK pathway (21) .
Ovarian cancer usually presents as locally advanced disease with involvement of the peritoneal cavity and the use of bevacizumab is under investigation in several clinical trials. Here we hypothesized that the cross-talk between cancer and endothelial cells would induce an activated ECs profile responsible for bevacizumab resistance and the constitution of a vascular niche. We demonstrated that the cross-talk between ovarian cancer cells and established human umbilical vein endothelial cell line (HUVECs), resulted in an activation of Akt pathway among others. To model tumor endothelium, we used the Akt-activated endothelial cells (E4 + ECs) to study the involvement of the endothelial component in the resistance to anti-angiogenic therapy (22) .
We demonstrated that in the setting of tumor-endothelial cross-talk, ECs activation of Pi3k/Akt pathway induces an autocrine loop through the proangiogenic factor fibroblast growth factor 2 (FGF-2), bypassing the VEGF-R pathway. We demonstrated that blocking FGF-2 would efficiently reverse the resistance to bevacizumab. These results propose the use of stroma directed synthetic therapy to overcome resistance in ovarian cancer. single stained channels were used for compensation, and fluorophore minus one (FMO) controls were used for gating (23) . Single stained channels were used for compensation and fluorophore minus one (FMO) controls were used for gating. Neutralizing anti FGF-2 assay. A monoclonal neutralizing mouse anti-FGF-2 antibody (Millipore, clone bFM-1) was used for FGF-2 neutralization at 1 µg/ml and 5 µg/ml with or without bevacizumab. Cell viability was determined by XTT assay after 2 days neutralization. E4 + ECs stimulated with 20 ng/ml of FGF-2 were used as positive controls. Isotypic IgG control was used as internal control, and serum-free medium as negative control. 
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Results
Cancer cell cross-talk with endothelial cells induces pro-survival signaling. Tumor endothelial heterogeneity and in particular endothelial Akt activation has been previously reported (24) . Ovarian tumor vessels displayed heterogenous phospho-Akt staining (Fig. 1A) . To investigate the role of soluble factors in tumor-endothelial cells communication, we established a trans-well co-culture system of HUVEC and ovarian cancer cells (OCCs). We used (i) established OCCs lines (OVCAR-3, SKOV-3), (ii) and two primary OCCs isolated from papillary serous ovarian cancers (GOC-2 and GOC-A2).
As shown in Figure 1B , we observed heterogeneous Akt phosphorylation in HUVECs. OVCAR-3 cells induced less Akt phosphorylation than the other cell lines tested. SKOV-3, which are highly resistant to chemotherapy and have metastatic features, induced the higher level of Akt activation. We confirmed the 'activated' phenotype in HUVEC by western blot (Supplementary Fig. S1 ).
E4
+ ECs display resistance to bevacizumab. We hypothesize that endothelium activation might play a role in bevacizumab resistance. The use of serum and cytokines to maintain HUVECs in culture might hinder cell autonomous effect. Thus to model a tumor associated endothelium, we used our recently generated endothelial cell line E4 + ECs that can survive in serumcytokine-free media (22) to study further mechanisms of resistance to bevacizumab. We first verified the presence of VEGF-A and VEGFR (mRNA and protein levels) in HUVECs and E4 + ECs (supplementary Fig. S2-A and B) .
We conducted several functional assays with E4 + ECs, their control HUVEC and HUVEC co-cultured with ovarian cancer cells (Figure 2A ). We evaluated (Fig. 2D) . Besides the pro-survival signaling, VEGF-A also induces endothelial cell migration and vessel formation (25) . Under serum-growth factor-free condition, we were not able to evaluate the motility of HUVEC in the presence or absence of VEGF-A (10, 25, 50ng/mL), or bevacizumab treatment. But we observed that in E4 + ECs, or HUVEC co-cultured with SKOV-3 condition medium, bevacizumab was not able to prevent wound closure ( Fig. 2E and supplementary Fig. S3 -B, S3-C).
In a tube formation assay, while HUVECs treated by bevacizumab alone or supplemented with VEGF-A resulted in unramified tube-like structures with dead ends, E4 + ECs or HUVEC co-cultured with SKOV-3 condition medium maintained the capacity to form assembled capillary-like structures ( Figure 2F and Supplementary Fig. S3-D 
+ ECs ( Supplementary Fig. S3-F) .
Inhibition of Akt-mediated survival pathways increases bevacizumab effect. We first showed that Akt phosphorylation was abrogated as early as 10 minutes after treatment with the pan-PI3K inhibitor LY294002 (10 µM) ( Fig.   3A and Supplementary Fig.S4-A) . LY294002 treatment alone did not decrease E4 + ECs viability, but co-treatment with bevacizumab reversed E4 + ECs resistance to anti-angiogenic therapies ( Fig. S4-E) . In all OCCs used in this study, while bevacizumab efficiently neutralizes VEGF-A, the expression of FGF-2 could still be detected ( Supplementary Fig. S4-F) . We observe that E4 + ECs treatment by bevacizumab is accompanied by a three-fold increase in FGF-2 mRNA and protein level. We also observed an increase in FGFR1 mRNA and in FGFR1 phosphorylation (Fig. 3C) . We then verified if FGF-2 was able to induce Akt activation and found that Akt phospohorylation could be detected in HUVEC as soon as 10 minutes after treatment with FGF-2 (10ng/mL) (Fig. 3D, left   panel ). An overnight treatment with FGF-2 shows that Akt phosphorylation in HUVEC cells is similar to the Akt phosphorylation observed in E4 + EC as shown by phospho-flow analysis (Fig. 3D, right panel) . Concordantly, the treatment of HUVEC by FGF-2 induced resistance to bevacizumab and reversed the inhibition of angiogenesic attributes ( Supplementary Fig.S5-A Inhibition of FGF2 signaling reversed bevacizumab resistance in E4 + ECs. To investigate if the inhibition of FGF-2 signaling would reverse bevacizumab resistance, we used a FGF-2 blocking antibody. We showed that neutralization of FGF-2 activity decreases Akt phosphorylation in E4 + EC.
We then showed a synergistic effect when anti-FGF-2 was added to Figure 4A ). We verified that blocking FGF-2 alone did not impact E4 + ECs survival. However, in the context of FGF-2 deprivation, bevacizumab resistance was reverted (Fig. 4B) . Finally, we also investigated the role of FGF-2 in the angiogenic attributes. Blocking FGF-2 alone has a minor effect on motility, but a drastic effect on tube formation, confirming the role of FGF-2 as a potent angiogenic factor ( Fig.4C   and 4D ). We then assessed the effect of the inhibition of FGFR activity using 
